RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

(Somewhat OT: TRGT) Targacept projects having $180 million in cash at year-end. They could afford multiple licensings. I've suggested a Cortex licensing to them in the past, though the overlap in relevant indications has always been a problem-- and have for a couple years suggested they diversify their portfolio beyond nicotinics. But that is the big question for TRGT--under their founding CEO, who had spent his entire professional life in the nicotinic area, they never moved outside of it. The question is how aggressively the new CEO will do so.

NP